Firibastat: A Novel Brain Aminopeptidase Inhibitor - A New Era of Antihypertensive therapy
Document Type
Article
Publication Date
4-3-2021
Publication Title
Current problems in cardiology
E-ISSN
1535-6280
Department(s)
Cardiology Division; Fellows and Residents
Abstract
Global incidence and prevalence of hypertension continues to increase and remains a significant challenge. The ever-increasing number of cases are due to comorbid conditions such as obesity and diabetes, as well as lifestyle indiscretions such as excessive salt intake. Hypertension, congestive heart failure, and kidney disease are all conditions resulting from abnormal Renin-Angiotensin-Aldosterone activation and adverse remodeling. Firibastat, a novel Brain Aminopeptidase inhibitor, may be able to help achieve blood pressure control in those with resistant hypertension. In this review article, we will discuss the biochemical pathway of firibastat and various trials assessing drug efficacy in animals and humans. This drug has the potential to curb the risk of uncontrolled hypertension and help improve long term cardiovascular morbidity and mortality.
First Page
100859
DOI
10.1016/j.cpcardiol.2021.100859
PubMed ID
33994025
Recommended Citation
Gupta, R., Alcantara, R., Popli, T., Tariq, U., Sood, A., Mahajan, S., Ayele, H., Rajeswaran, Y., & Vyas, A. (2021). Firibastat: A Novel Brain Aminopeptidase Inhibitor - A New Era of Antihypertensive therapy. LVHN Scholarly Works. Retrieved from https://scholarlyworks.lvhn.org/research-historical-works/78
DOI: 10.1016/j.cpcardiol.2021.100859